No­var­tis' ra­dio­phar­ma drug wins ap­proval in tough-to-treat prostate can­cer pa­tients

One of the key ways in which No­var­tis CEO Vas Narasimhan hopes to stave off gener­ic com­pe­ti­tion took a gi­ant leap for­ward Wednes­day af­ter­noon.

The FDA ap­proved Lu-PS­MA-617, No­var­tis’ ra­di­oli­gand pro­gram ac­quired in the $2.1 bil­lion buy­out of En­do­cyte back in 2018, to treat PS­MA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer. No­var­tis will brand the drug as Plu­vic­to, and a spokesper­son told End­points News that the drug’s whole­sale ac­qui­si­tion cost will be set at $42,500 per dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER